{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004183","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.296589+00:00","generated_at":"2026-06-20T17:45:01.913159+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Karyopharm reports preliminary FY2022 revenue ~$157.7M, extends cash runway to late 2025","bullets":["Preliminary FY2022 total revenue ~$157.7M; XPOVIO US net revenue ~$120.4M, up 22% YoY.","Q4 2022 total revenue ~$34.2M; XPOVIO US net revenue ~$31.1M.","Cash & investments ~$279.0M as of Dec 31, 2022, following $165M private placement; runway extended to late 2025.","Initiated Phase 3 EC-042 for selinexor in TP53 wild-type endometrial cancer; partnership with Foundation Medicine for companion Dx.","Planning to initiate Phase 3 MF study in 1H 2023; updated Phase 1 selinexor+ruxolitinib data in MF expected in 1H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004183","json":"https://secwatch.observer/filing/0001193125-23-004183.json","markdown":"https://secwatch.observer/filing/0001193125-23-004183.md","text":"https://secwatch.observer/filing/0001193125-23-004183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523004183/0001193125-23-004183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523004183/d435746d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:45:01.913159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cbd21b2007542f1cc288df98f1beacd0595fcfd7","claim":"Karyopharm Therapeutics Inc. reported fourth quarter and full year 2022 results: revenue approximately $34.2 million for the fourth quarter 2022 and approximately $157.7 million for the full year 2022.","evidence_excerpt":"On January 9, 2023, Karyopharm Therapeutics Inc. (the “Company”) announced preliminary unaudited fourth quarter and full year 2022 total revenue and U.S. XPOVIO ® (selinexor) net product revenue estimates, and outlined its 2022 achievements and 2023 objectives.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312523004183/0001193125-23-004183-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2022"},{"label":"Revenue","value":"approximately $34.2 million for the fourth quarter 2022 and approximately $157.7 million for the full year 2022"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}